[Future of malignant stage I melanoma. Immunology and immunotherapy].
Nicolas
J F
JF
INSERM U 80, Pavillon P, Hôpital E.-Herriot, Lyon, France.
Berthier
O
O
Trillet-Lenoir
V
V
Claudy
A
A
Revillard
J P
JP
D000951:Antigens, Neoplasm / Q000032:analysis*; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends*; D007372:Interferons / Q000627:therapeutic use; D016246:Lymphocytes, Tumor-Infiltrating; D008545:Melanoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000032:analysis*; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D013601:T-Lymphocytes
D000951:Antigens, Neoplasm; D016207:Cytokines; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D007372:Interferons
Le futur du mélanome malin de stade I. immunologie et immunothérapie du mélanome malin.